Therapy News and Research

RSS

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

Columbus hospital receives PPMD grant to conduct clinical testing for Duchenne

Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), will award a $600,000 grant to Nationwide Children's Hospital in Columbus, Ohio to conduct clinical testing of a promising gene therapy technique for muscle disease.

10 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Scientists identify compound to inhibit wild-type HIV-1 protease

Drug resistance remains a major problem in combating HIV infection, but a different approach to drug development could be the answer.Current viral inhibitors target the HIV-1 protease function with a competitive mechanism. Writing in the BJ ChemBio Knowledge Environment of the Biochemical Journal, Max Chang and colleagues from the Scripps Research Institute, La Jolla, suggest that pharmaceutical companies look at compounds that use an allosteric non-competitive mechanism of inhibition.

10 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and six months ended June 30, 2010.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.

10 Aug 2010

Cardium second-quarter net loss decreases to $0.7 million

Cardium Therapeutics today reported highlights and financial results for its second quarter ended June 30, 2010.

10 Aug 2010

ACADIA second-quarter net loss decreases to $4.3 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Poniard second-quarter net loss decreases to $6.5 million

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Scientists work towards creating a vaccine for Parkinson's disease

Nina Brown, 68, and millions of others with a debilitating neurological condition called Parkinson's disease are counting on researchers for a cure. At The University of Texas Health Science Center at Houston (UTHealth), protein chemists are working to develop a therapeutic vaccine.

10 Aug 2010

Ikaria announces voluntary recall of INOMAX DS drug-delivery system in US and Canada

Ikaria, Inc. announced today that its INOMAX® DS drug-delivery systems in the United States are being voluntarily recalled due to the potential failure of a pressure switch which may have an impact on the administration of INOMAX® (nitric oxide) for inhalation to patients. This potential failure was identified by Ikaria as part of its ongoing quality monitoring and review processes. This class I recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). All INOMAX DS systems in Canada also are being voluntarily recalled.

10 Aug 2010

Vena cava blood clot filters may cause potential life-threatening complications: Study

Two specific types of vena cava filters, devices used to prevent blood clots from reaching the lungs, appear to have evidence of fracturing inside the body, with some fractured fragments traveling to the heart and causing potentially life-threatening complications, according to a report posted online today that will appear in the November 8 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Aug 2010

Scientist develops nano-methods to destroy tumors with fewer side effects

Though a valuable weapon against cancerous tumors, radiation therapy often harms healthy tissue as it tries to kill malignant cells. Now, Prof. Israel Gannot of Tel Aviv University's Department of Biomedical Engineering is developing a new way to destroy tumors with fewer side effects and minimal damage to surrounding tissue.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

Therapy News and Research

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Columbus hospital receives PPMD grant to conduct clinical testing for Duchenne

China Pharma second-quarter revenue increases 22% to $16.6 million

Scientists identify compound to inhibit wild-type HIV-1 protease

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Endo to acquire Penwest for $5.00 per share

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Cardium second-quarter net loss decreases to $0.7 million

ACADIA second-quarter net loss decreases to $4.3 million

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Poniard second-quarter net loss decreases to $6.5 million

Scientists work towards creating a vaccine for Parkinson's disease

Ikaria announces voluntary recall of INOMAX DS drug-delivery system in US and Canada

Vena cava blood clot filters may cause potential life-threatening complications: Study

Scientist develops nano-methods to destroy tumors with fewer side effects

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News